ELI LILLY & Co SEC Filings

Eli Lilly and Company director J. Erik Fyrwald elected to receive 9.336 stock units tied to Eli Lilly common stock on 12/15/2025 instead of cash compensation. The units were valued at $1,062.19 each under the Lilly Directors' Deferral Plan and will be settled in shares of common stock after his separation from service.

After this transaction, Fyrwald beneficially owns 75,101.227 shares of Eli Lilly common stock in direct holdings.

Eli Lilly & Co. director Ralph Alvarez reported acquiring 11.062 shares of Eli Lilly common stock on 12/15/2025 at a price of $1,062.19 per share. According to the filing, these shares were credited as stock units under the Lilly Directors' Deferral Plan in lieu of cash compensation and will be settled in shares of common stock after he separates from service as a director.

After this transaction, Alvarez beneficially owned 55,467.718 shares of Eli Lilly common stock directly and 758 shares indirectly through a trust, with the indirect ownership reported only to the extent of his pecuniary interest.

Eli Lilly and Company reported an initial insider ownership filing for a director. The reporting person is identified as a director of Eli Lilly and holds 2,000 shares of the company’s common stock in direct ownership. This type of filing gives investors visibility into how many shares a company insider beneficially owns at the time they become a reporting person.

The document is signed under a power of attorney authorization, indicating that the signature was provided on the director’s behalf. There are no derivative securities, such as options or warrants, listed as beneficially owned in this filing.

Eli Lilly & Co. (LLY) director Lilly Endowment Inc. reported open-market sales of Eli Lilly common stock on 11/25/2025. The Endowment sold 5,043 shares at a weighted average price of $1,108.71, 9,249 shares at a weighted average price of $1,109.449, and 1,340 shares at a weighted average price of $1,110.527, for a total of 15,632 shares sold.

After these transactions, Lilly Endowment Inc. beneficially owned 92,196,978 shares of Eli Lilly common stock, held directly. The prices reported reflect multiple trades within narrow ranges for each block of shares. This filing is identified as the second of two Forms 4 filed by the reporting person on the same date, covering transactions numbered 31 through 33 of 33 total transactions.

Lilly Endowment Inc., a director-level reporting person of Eli Lilly & Co (LLY), reported a series of open-market sales of Eli Lilly common stock on 11/25/2025. The Form 4 lists 30 separate sale transactions, each coded as an "S" for sale, with weighted average prices including $1,073.735 and $1,107.48 per share, and footnotes detailing underlying trade ranges from $1,073.78 to $1,107.95. After completing these reported sales, Lilly Endowment Inc. beneficially owned 92,212,610 shares of Eli Lilly common stock, held directly. This filing is identified as the first of two Forms 4 filed the same day, covering transactions numbered 1 through 30 of 33 total.

Lilly Endowment Inc., a director and more than 10% owner of Eli Lilly & Co (LLY), reported multiple sales of Eli Lilly common stock on 11/24/2025. The largest block shown was 120,016 shares sold at a weighted average price of $1,068.175 per share, with additional smaller sales the same day at weighted average prices between about $1,069.477 and $1,073.597 per share.

After these transactions, Lilly Endowment directly beneficially owned 92,359,671 shares of Eli Lilly common stock. The prices reported are weighted averages for multiple trades within narrow price ranges, and the reporting person has indicated a willingness to provide detailed trade breakdowns upon request.

Eli Lilly & Co. (LLY) reported a series of share sales by a 10% owner on 11/21/2025. The Form 4 shows Lilly Endowment Inc., filing as a single reporting person, disposing of multiple blocks of common stock in open-market transactions coded "S" for sale.

The reported trades cover numerous small tranches, such as 9,871 shares at a weighted average price of $1,050.272 and 23,916 shares at $1,059.658, with additional sales at prices generally between about $1,050 and $1,066.15. After these transactions, the reporting person beneficially owned 92,501,978 shares of Eli Lilly common stock, held directly.

Lilly Endowment Inc. filed a Form 144 notice covering a proposed sale of 305,000 shares of Eli Lilly and Company common stock through Fidelity Capital Markets, with an aggregate market value of $323,208,500. The notice lists 945,383,757 Eli Lilly shares outstanding. The Endowment’s shares being sold trace back to a large historical gift; it reports acquiring 38,400,000 Eli Lilly common shares via a gift from the J.K. Lilly Sr. Trust dated in the 1930s–1940s.

The filing also details extensive recent selling activity by Lilly Endowment. Over the past three months, it executed multiple Eli Lilly stock sales on the NYSE and NASDAQ, including transactions such as 351,015 shares on 10/01/2025 for gross proceeds of $284,653,451.48 and 305,000 shares on 11/12/2025 for $308,411,211.50. Individual daily trades during this period often exceeded 100,000 shares, with gross proceeds frequently above $80 million per day.

Eli Lilly and Company reported that its Board of Directors has elected Carolyn R. Bertozzi, Ph.D. as a new director, effective December 8, 2025. She is 59 and holds key academic roles at Stanford University, including Professor of Chemistry, Chemical & Systems Biology, and Radiology, and serves as an Investigator of the Howard Hughes Medical Institute.

Dr. Bertozzi will join Lilly’s Science and Technology Committee and the Ethics and Compliance Committee, bringing additional scientific and governance expertise. The Board has determined that she is independent under New York Stock Exchange standards and the company’s own guidelines. She will stand for election by shareholders at the annual meeting in May 2026 and will receive compensation under Lilly’s standard director compensation program.